Drug Trial News

RSS

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.

12 Dec 2025

UC Irvine receives funding for clinical trial of neural stem cell therapy for Huntington's disease

Leslie M. Thompson, Donald Bren Professor of psychiatry and human behavior as well as neurobiology and behavior at the University of California, Irvine, has received an $11,999,933 grant from the California Institute for Regenerative Medicine for an unprecedented clinical trial of a novel neural stem cell therapy for Huntington's disease.

12 Dec 2025

Etomidate proves safer than ketamine for emergency intubations

Doctors treating seriously ill patients in an emergency setting may want to give the sedative etomidate, rather than ketamine, while placing a breathing tube, according to a randomized trial published Dec. 9 in the New England Journal of Medicine.

12 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Varenicline helps young people quit nicotine vaping regardless of cannabis use

Adolescent and young adult nicotine vaping has become an urgent public health concern, as 2024 marked the first year that nicotine vaping was the most initiated drug.

12 Dec 2025

Most clinical trials fail to reflect America’s racial and ethnic diversity

A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and Hispanic individuals.

12 Dec 2025

Single-dose pill shows promise against antibiotic-resistant gonorrhoea

A single-dose oral medication called zoliflodacin shows promise as a new treatment for antibiotic-resistant gonorrhoea, according to a phase 3 clinical trial published in The Lancet.

11 Dec 2025

Cleveland Clinic reports promising results for breast cancer vaccine from final Phase 1 data

Cleveland Clinic researchers are presenting final Phase 1 data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

11 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

Van Andel Institute and Cure Parkinson's extend major Parkinson's drug trial initiative

Van Andel Institute and Cure Parkinson's have renewed a funding agreement to support the International Linked Clinical Trials Program, the world's largest drug repurposing clinical trial initiative for Parkinson's disease.

10 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Landmark RSI trial reshapes sedative selection for emergency airway management

9 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

9 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

1
2
3
4
...
1161
Next

Drug Trial News

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

UC Irvine receives funding for clinical trial of neural stem cell therapy for Huntington's disease

Etomidate proves safer than ketamine for emergency intubations

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

Varenicline helps young people quit nicotine vaping regardless of cannabis use

Most clinical trials fail to reflect America’s racial and ethnic diversity

Single-dose pill shows promise against antibiotic-resistant gonorrhoea

Cleveland Clinic reports promising results for breast cancer vaccine from final Phase 1 data

Antibody therapy clears residual multiple myeloma in early trial

Van Andel Institute and Cure Parkinson's extend major Parkinson's drug trial initiative

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Landmark RSI trial reshapes sedative selection for emergency airway management

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

TXA reduces the need for blood transfusion in patients undergoing high-risk non-cardiac surgery

Combination therapy may boost survival for people with aggressive lymphoma

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News